CD5+ Dendritic Cell Modulation for Psoriasis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psoriasis and other inflammatory diseases do not effectively target the specific role of CD5+ dendritic cells in promoting inflammatory responses, and there is a need for methods to modulate CD5 expression to manage disease severity and progression.
Innovation Solution
The development of methods and compositions to detect and modulate CD5+ cells, including the use of CD5 modulation agents such as FLT3-L, GM-CSF, TNF-α, and LTα/β to regulate CD5 expression and function in dendritic cells, which can inhibit or enhance immune responses depending on the disease context.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current psoriasis therapies (biologic immunotherapy, psoralen, PUVA) are used, then disease symptoms are reduced, but the treatment does not effectively target the specific role of CD5+ dendritic cells and lacks precision in modulating immune responses
Solution Approach 1:
The invention segments the immune system into specific CD5+ dendritic cell populations that can be independently targeted and modulated. By focusing on CD5+ DCs as a distinct subset rather than treating all immune cells uniformly, the therapy achieves precise targeting of the specific cell type responsible for promoting inflammatory responses in psoriasis.
Solution Approach 2:
The invention changes the parameter of immune cell targeting from general immunosuppression to specific modulation of CD5+ DC populations. By using agents that selectively affect CD5+ DCs (such as modulating their numbers, activation state, or cytokine production), the treatment achieves disease efficacy while adapting to the specific pathogenic role of these cells.
2Object-generated harmful factors
If CD5+ dendritic cell numbers or activity are reduced, then inflammatory responses are decreased, but current therapies do not specifically achieve this reduction
Solution Approach 1:
The invention uses CD5+ dendritic cells as the intermediary target between the therapeutic agent and the harmful inflammatory response. By specifically reducing or modulating CD5+ DC numbers or activity, the therapy indirectly reduces the harmful inflammatory responses they promote, while maintaining specificity through the CD5+ DC marker.
Solution Approach 2:
The invention extracts or removes the specific pathogenic CD5+ dendritic cell population from the immune system to eliminate their harmful function. By selectively depleting or suppressing CD5+ DCs rather than treating all immune cells, the therapy directly addresses the source of harmful inflammatory responses while maintaining ease of implementation through targeted approaches.
3Object-affected harmful factors
If general immunosuppression is used to treat psoriasis, then inflammatory symptoms improve, but the specific role of CD5+ DCs in disease pathogenesis is not addressed
Solution Approach 1:
The invention segments the immune system into functionally distinct subsets, specifically identifying CD5+ dendritic cells as the pathogenic subset in psoriasis. By targeting this segmented population rather than applying general immunosuppression to all immune cells, the therapy addresses the specific role of CD5+ DCs while maintaining information about which cells are truly responsible for disease pathogenesis.
Data Source
AI summary
The present disclosure provides for methods and compositions for the modulation of CD5 in a subject. Also provided are methods of detecting and monitoring diseases, such as inflammatory and autoimmune diseases.